GAIDANO, Valentina
 Distribuzione geografica
Continente #
NA - Nord America 2.323
EU - Europa 1.255
AS - Asia 794
AF - Africa 20
SA - Sud America 18
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.421
Nazione #
US - Stati Uniti d'America 2.271
IT - Italia 456
CN - Cina 296
SG - Singapore 187
IE - Irlanda 151
SE - Svezia 127
DE - Germania 75
FR - Francia 75
GB - Regno Unito 64
VN - Vietnam 64
UA - Ucraina 59
AT - Austria 51
CA - Canada 51
IN - India 50
FI - Finlandia 48
JP - Giappone 39
HK - Hong Kong 33
ID - Indonesia 32
NL - Olanda 30
KR - Corea 28
PL - Polonia 28
BE - Belgio 22
IR - Iran 14
BR - Brasile 13
CH - Svizzera 12
AU - Australia 10
CZ - Repubblica Ceca 10
PK - Pakistan 10
TR - Turchia 8
GR - Grecia 7
SA - Arabia Saudita 7
ZA - Sudafrica 7
DK - Danimarca 6
IL - Israele 6
NG - Nigeria 6
RU - Federazione Russa 6
TW - Taiwan 6
HR - Croazia 5
IQ - Iraq 5
ES - Italia 4
MY - Malesia 3
NO - Norvegia 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
UZ - Uzbekistan 3
AR - Argentina 2
BG - Bulgaria 2
CI - Costa d'Avorio 2
CL - Cile 2
HU - Ungheria 2
JO - Giordania 2
LT - Lituania 2
MA - Marocco 2
MK - Macedonia 2
RO - Romania 2
SN - Senegal 2
BD - Bangladesh 1
CO - Colombia 1
EG - Egitto 1
EU - Europa 1
MX - Messico 1
Totale 4.421
Città #
Chandler 339
Santa Clara 151
Dublin 150
Singapore 144
Fairfield 121
Beijing 108
Torino 98
Nyköping 85
Fremont 78
Ashburn 77
Ann Arbor 75
Woodbridge 67
Wilmington 59
Jacksonville 58
Houston 57
Medford 55
Turin 50
Vienna 49
Redwood City 48
Seattle 45
Dearborn 43
Princeton 41
Columbus 39
Cambridge 38
Pisa 34
Villeurbanne 32
Jakarta 30
Dong Ket 29
New York 25
Guangzhou 23
Warsaw 23
Helsinki 22
Brussels 21
Shanghai 21
Québec 17
Los Angeles 14
Menlo Park 13
Milan 13
Viterbo 13
Ottawa 12
San Diego 12
Dallas 11
Boardman 10
Nanjing 10
Washington 10
Hangzhou 9
Hebei 9
Hefei 9
Rome 9
Delhi 8
Tai Wan 8
Tokyo 8
Boston 7
Florence 7
Frankfurt am Main 7
Hong Kong 7
Paris 7
Riverside 7
Toronto 7
Uppsala 7
Xian 7
Abuja 6
Chennai 6
Dronten 6
Duncan 6
Durban 6
Epsom 6
Tianjin 6
Amsterdam 5
Bari 5
Cassano Magnago 5
Changchun 5
Dammam 5
Montreal 5
Novara 5
Novate Milanese 5
Reston 5
San Jose 5
Seoul 5
Valdagno 5
Zhengzhou 5
Buffalo 4
Catania 4
Düsseldorf 4
Falls Church 4
Hamburg 4
Jinan 4
Kunming 4
Liverpool 4
London 4
Norwalk 4
Phoenix 4
San Mateo 4
Sesto Fiorentino 4
Taipei 4
West Jordan 4
Wuhan 4
Basel 3
Belgrade 3
Bloomsbury 3
Totale 2.773
Nome #
PROCEEDINGS OF THE MERCK & ELSEVIER YOUNG CHEMISTSSYMPOSIUM 301
DHODH inhibitors and leukemia: an emergent interest for new myeloid differentiation agents 250
Emerging therapies for acute myeloid leukaemia using hDHODH inhibitors able to restore in vitro and in vivo myeloid differentiation 239
Clinical significance of TFR2 and EPOR expression in bone marrow cells in myelodysplastic syndromes 218
Detection of BCR-ABL T315I mutation by peptide nucleic acid directed PCR clamping and by peptide nucleic acid FISH 183
Development of cellular and humoral response against WT1 protein vaccination in mice 180
The Wilms' tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy 172
Development of Potent Human Dihydroorotate Dehydrogenase Inhibitors Able to Induces Myeloid Differentiation 162
Design and application of a novel PNA probe for the detection at single cell level of JAK2V617F mutation in Myeloproliferative Neoplasms 161
ERYTHROFERRONE EXPRESSION LEVELS IN MYELODYSPLATIC SYNDROMES SHOW CLINICAL RELEVANCE 159
Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study 130
In vitro myeloid differentiation using a new generation of potent human dihydroorotate dehydrogenase (hDHODH) inhibitors 119
Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors 118
Inhibition of bromodomain and extra-terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia 118
A differentiating and apoptotic therapy for Acute Myeloid Leukaemia using MEDS433, a potent human Dihydroorotate Dehydrogenase inhibitor 115
TFR2 AND EpoR EXPRESSION AT DIAGNOSIS AS POSSIBLE PREDICTORS OF ERYTHROPOIETIN TREATMENT RESPONSE IN MDS PATIENTS 114
Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors 107
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold: SAR of the Biphenyl Moiety 105
In vitro myeloid differentiation using a new generation of potent human dihydroorotate dehydrogenase inhibitors 93
Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia. 90
SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience 89
High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis. 84
Targeting myeloid differentiation using potent human dihydroorotate dehydrogenase (hDHODH) inhibitors 84
Emerging therapies for acute myeloid leukaemia using hDHODH inhibitors 82
A differentiating and apoptotic therapy for acute myeloid leukaemia using potent human dihydroorotate dehydrogenase inhibitors. 78
Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients 75
A new pro-apoptotic therapy for Acute Myeloid Leukaemia using MEDS433, a potent human Dihydroorotate Dehydrogenase inhibitor 74
Design and Application of a Novel PNA Probe for the Detection At Single Cell Level of JAK2(V617F) Mutation 72
The synergism between DHODH inhibitors and dipyridamole leads to metabolic lethality in acute myeloid leukemia 71
Improvement of in vivo pharmacokinetic profile of M433, a potent and innovative hDHODH inhibitor. 69
The inhibition of human DHODH by M433 leads to differentiation and apoptosis in acute myeloid leukemia 63
Prognostic significance of The Wilms’ Tumor-1 (WT1) rs16754 polymorphism in acute myeloid leukemia 61
Meds433, a New Dihydroorotate Dehydrogenase Inhibitor, Induces Apoptosis and Differentiation in Acute Myeloid Leukemia 58
Apoptotic and differentiating therapy for AML using potent human dihydroorotate dehydrogenase inhibitor 56
Targeting chronic myeloid leukemia stem/progenitor cells using venetoclax-loaded immunoliposome 55
Hydroxylated heterocycles as a bioisosteric tool to Modulate the carboxylic function into design potent human Dihydroorotate Dehydrogenase inhibitors 55
Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia 49
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine 48
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: SAR of the Aryloxyaryl Moiety 45
New human dihydroorotate dehydrogenase inhibitors able to restore myeloid differentiation in AML 44
Induction of robust humoral immunity against SARS-CoV-2 after vaccine administration in previously infected haematological cancer patients 36
Quality of life and physicians' perception in myelodysplastic syndromes 36
Shedding Light on Targeting Chronic Myeloid Leukemia Stem Cells 14
The Synergism Between DHODH Inhibitors and Dipyridamole Induces Apoptosis and Differentiation in Acute Myeloid Leukemia 4
Totale 4.536
Categoria #
all - tutte 14.787
article - articoli 0
book - libri 0
conference - conferenze 6.509
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.296


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020347 0 0 0 0 0 67 73 39 44 45 46 33
2020/2021583 32 52 48 28 62 38 35 32 49 60 46 101
2021/2022665 24 21 38 50 34 34 42 31 22 77 185 107
2022/20231.099 95 128 31 115 91 230 60 79 118 47 71 34
2023/2024439 62 66 30 27 22 62 16 12 5 48 25 64
2024/2025569 27 63 49 135 227 68 0 0 0 0 0 0
Totale 4.536